Immutep Limited (FRA:YP1B)

Germany flag Germany · Delayed Price · Currency is EUR
0.1270
+0.0030 (2.42%)
At close: Sep 29, 2025
2.42%
Market Cap218.10M
Revenue (ttm)2.82M
Net Income (ttm)-34.30M
Shares Outn/a
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume105
Open0.1270
Previous Close0.1240
Day's Range0.1270 - 0.1270
52-Week Range0.1080 - 0.2140
Betan/a
RSI54.67
Earnings DateSep 10, 2025

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase II... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 31
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol YP1B
Full Company Profile

Financial Performance

In 2025, Immutep's revenue was 5.04 million, an increase of 31.28% compared to the previous year's 3.84 million. Losses were -61.43 million, 43.8% more than in 2024.

Financial numbers in AUD Financial Statements

News

There is no news available yet.